-
North China Pharmaceutical’s Ormutivimab Approved for Pediatric Use in China
•
North China Pharmaceutical Group Corporation (SHA: 600812) has announced that it has received approval from the National Medical Products Administration (NMPA) for a new indication for its Category 1 therapeutic biologic, ormutivimab. The drug, a recombinant humanized rabies virus monoclonal antibody (mAb), is now approved for use in children aged…
-
Round 8 VBP Tender Results: RMB 3.775 Billion Awarded Across 152 Manufacturers
•
The official results of Round 8 of China’s national Volume-Based Procurement (VBP) tender program have been released, detailing the volumes and provinces awarded for each tender. The round saw RMB 3.775 billion (USD 550 million) in bid spots distributed among a total of 152 manufacturers, resulting in over 252 valid…
